Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. filed this Form 8-K on November 21, 2018, to report the completion of a private placement transaction. The Company, incorporated in Nevada, entered into a Securities Purchase Agreement with three institutional investors to raise capital through the sale of Convertible Notes and Common Stock Purchase Warrants.
Key Financial Metrics and Transaction Details
- Total Proceeds: $300,000 (3 investors x $100,000 purchase price).
- Principal Amount of Notes: $324,000 total (3 investors x $108,000 principal).
- Interest Rate: 8% per annum.
- Maturity Date: November 15, 2019.
- Warrant Coverage: 5,955,882 shares total (3 investors x 1,985,294 shares).
- Warrant Exercise Price: $0.0272 per share.
- Warrant Term: 5 years.
- Conversion Price: 70% of the Market Price (defined as the lowest trading price during the 20 trading days preceding conversion).
The filing does not provide specific data on the Company's current revenue, profit, cash flow, operating margins, existing debt levels, or liquidity ratios outside of this specific transaction.
Material Changes
This filing represents a material change in the Company's capital structure and obligations. The Company has incurred a new direct financial obligation of $324,000 in principal debt and issued unregistered equity securities (warrants) that may result in significant future dilution. The transaction was executed under Section 4(a)(2) of the Securities Act and Rule 506(b).
Outlook, Risks, and Unusual Items
- Anti-Dilution Provisions: The Warrants include a full ratchet anti-dilution adjustment, which could significantly lower the exercise price in the event of future issuances of common stock at a lower price.
- Conversion Mechanics: The conversion price is based on a discount to the lowest trading price over a 20-day period, which may incentivize conversion during periods of low stock price volatility or decline.
- Covenants: The Notes are subject to customary covenants and events of default, the specific terms of which are detailed in the attached exhibits.
- Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial performance.
Investor Verification Checklist
- Verify the Company's current cash position to assess its ability to service the 8% interest and principal repayment by November 2019.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) to understand specific covenants and default triggers.
- Assess the potential dilution impact of the 5,955,882 warrant shares, particularly considering the full ratchet anti-dilution feature.
- Confirm the Company's recent trading volume and price history to evaluate the likely conversion price of the Notes.